HK1215174A1 - 針對活化蛋白 的人源化單克隆抗體及其用途 - Google Patents

針對活化蛋白 的人源化單克隆抗體及其用途

Info

Publication number
HK1215174A1
HK1215174A1 HK16103170.8A HK16103170A HK1215174A1 HK 1215174 A1 HK1215174 A1 HK 1215174A1 HK 16103170 A HK16103170 A HK 16103170A HK 1215174 A1 HK1215174 A1 HK 1215174A1
Authority
HK
Hong Kong
Prior art keywords
monoclonal antibodies
antibodies against
activated protein
humanized monoclonal
against activated
Prior art date
Application number
HK16103170.8A
Other languages
English (en)
Inventor
Xiao-Yan Zhao
Zhuozhi Wang
Ji-Yun Kim
Ying Zhu
Jan Tebbe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1215174A1 publication Critical patent/HK1215174A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16103170.8A 2012-11-29 2016-03-18 針對活化蛋白 的人源化單克隆抗體及其用途 HK1215174A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731368P 2012-11-29 2012-11-29
PCT/US2013/072137 WO2014085527A1 (en) 2012-11-29 2013-11-27 Humanized monoclonal antibodies against activated protein c and uses thereof

Publications (1)

Publication Number Publication Date
HK1215174A1 true HK1215174A1 (zh) 2016-08-19

Family

ID=50828440

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103170.8A HK1215174A1 (zh) 2012-11-29 2016-03-18 針對活化蛋白 的人源化單克隆抗體及其用途

Country Status (17)

Country Link
US (2) USRE49099E1 (zh)
EP (1) EP2925360A4 (zh)
JP (1) JP2016501875A (zh)
KR (1) KR20150088853A (zh)
CN (1) CN104936618A (zh)
AR (1) AR093672A1 (zh)
AU (1) AU2013352260A1 (zh)
BR (1) BR112015012458A2 (zh)
CA (1) CA2892748A1 (zh)
HK (1) HK1215174A1 (zh)
IL (1) IL238920A0 (zh)
MX (1) MX2015006738A (zh)
RU (1) RU2015125343A (zh)
SG (1) SG11201504035PA (zh)
TW (1) TW201437229A (zh)
UY (1) UY35160A (zh)
WO (1) WO2014085527A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
CN115611986A (zh) * 2021-07-13 2023-01-17 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5279956A (en) 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
EP1322749B1 (en) 2000-10-02 2010-04-14 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor
US20030203355A1 (en) 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
JP4829609B2 (ja) * 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
PT1963368E (pt) 2005-12-13 2012-09-14 Lilly Co Eli Anticorpos anti-il-17
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
CN101646690B (zh) 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
US8039597B2 (en) 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008316661B2 (en) * 2007-10-26 2013-05-23 Oklahoma Medical Research Foundation Monoclonal antibodies against activated and unactivated protein C
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof

Also Published As

Publication number Publication date
EP2925360A1 (en) 2015-10-07
RU2015125343A (ru) 2017-01-11
TW201437229A (zh) 2014-10-01
AR093672A1 (es) 2015-06-17
CN104936618A (zh) 2015-09-23
AU2013352260A1 (en) 2015-06-11
IL238920A0 (en) 2015-07-30
US9657111B2 (en) 2017-05-23
MX2015006738A (es) 2015-08-05
BR112015012458A2 (pt) 2018-02-06
EP2925360A4 (en) 2016-07-13
KR20150088853A (ko) 2015-08-03
UY35160A (es) 2014-06-30
CA2892748A1 (en) 2014-06-05
USRE49099E1 (en) 2022-06-07
US20150322164A1 (en) 2015-11-12
WO2014085527A1 (en) 2014-06-05
JP2016501875A (ja) 2016-01-21
SG11201504035PA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
HUS2000056I1 (hu) ANTI-PD-L1 ellenanyagok és alkalmazásaik
HK1219965A1 (zh) 對磷脂醯肌醇蛋白聚糖 特異的人單克隆抗體及其用途
IL232219B (en) Human or humanized antibodies against tar-dna-binding protein 43kda and their uses
HK1209137A1 (zh) 人源化 抗體
EP3060581A4 (en) Anti-pd-l1 monoclonal antibodies and fragments thereof
EP2748199A4 (en) ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE
LT3219729T (lt) Interleukino-31 monokloninis antikūnas
EP2834271A4 (en) HUMANIZED AND CHIMERIC ANTI-FACTOR BB ANTIBODIES AND USES THEREOF
EP2841453A4 (en) HUMANIZED AND CHIMERIC C3 ANTI-FACTOR ANTIBODIES AND USES THEREOF
EP2668210A4 (en) ANTI-KIT ANTIBODIES AND ITS USES
EP2742067A4 (en) MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
EP2830660A4 (en) ANTI-SEMA4D ANTIBODIES AND EPITOPES
EP2746394A4 (en) ANTIBODY AND COMPOSITION CONTAINING THE SAME
EP2593475A4 (en) ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
HK1212896A1 (zh) 針對活化蛋白 的單克隆抗體
HK1215174A1 (zh) 針對活化蛋白 的人源化單克隆抗體及其用途
SG10201705841YA (en) Monoclonal antibody against muramyl peptides
HK1223950A1 (zh) 單克隆 抗體及其用途
EP2718321A4 (en) ANTI-FRICTION ANTIBODIES AND USES THEREOF
EP3066122A4 (en) Pre-haptoglobin-2 monoclonal antibodies and uses thereof
EP2771689A4 (en) PEPTIDES USP2A AND ANTIBODIES
EP2881467A4 (en) MONOCLONAL ANTIBODY DIRECTED AGAINST MIDKINE PROTEIN OF HUMAN ORIGIN
PL398829A1 (pl) Przeciwciala poliklonalne klasy IgY specyficzne wobec bialka Efb, sposób ich wytwarzania oraz ich zastosowanie
PL398828A1 (pl) Przeciwciala poliklonalne klasy IgY specyficzne wobec bialka Map, sposób ich wytwarzania oraz ich zastosowanie